Education
This week on Hormone Insight: the fallout from the ADA 2026 Scientific Sessions, where retatrutide — a triple GIP/GLP-1/glucagon agonist — delivered nearly 2 points of A1C and about 15% weight loss in type 2 diabetes (TRANSCEND-T2D-1). Plus CagriSema vs semaglutide head-to-head, finerenone in chronic kidney disease without diabetes, the new ADA/EASD type 1 diabetes consensus, and a Hormone Classic revisit of SUSTAIN-6 — the outcome bar every new drug still has to clear.
Segments:
• Trial of the Week — Retatrutide in type 2 diabetes (TRANSCEND-T2D-1, The Lancet)
• Quick Hit 1 — CagriSema vs semaglutide (REIMAGINE 2, Lancet Diabetes & Endocrinology)
• Quick Hit 2 — Finerenone in CKD without diabetes (FIND-CKD, NEJM)
• Guideline & FDA Watch — ADA/EASD type 1 diabetes in adults: 2026 consensus update
• Hormone Classic — SUSTAIN-6 (semaglutide cardiovascular outcomes, 2016)
⏱ Chapters
00:00 Cold open
00:38 Welcome & disclaimer
01:02 This week
01:47 Trial of the Week — Retatrutide (TRANSCEND-T2D-1)
03:51 The Appraisal
04:59 Bottom line — retatrutide
05:29 Quick Hit 1 — CagriSema vs semaglutide
06:54 Quick Hit 2 — Finerenone in CKD without diabetes
08:04 Guideline & FDA Watch — ADA/EASD type 1 diabetes
09:20 Hormone Classic — SUSTAIN-6
10:40 The Bottom Line
11:23 Sign-off
References & written summary: hormoneinsight.com/twide-2026-06-27
For healthcare professionals. Educational, not individual medical advice.
Subscribe for a new episode every Saturday. #diabetes #endocrinology #GLP1